ClinicalTrials.gg
CompletedNCT01311648Updated Dec 5, 2023Results posted

BAY81-8973 Pediatric Safety and Efficacy Trial

A Phase 3 interventional study of Recombinant Factor VIII (Kovaltry, BAY81-8973) and Recombinant Factor VIII (Kovaltry, BAY81-8973) in Haemophilia A, sponsored by Bayer. Completed at 43 sites in 17 countries. Open to male participants aged 0 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
0 Years to 12 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Hemophilia A by Bayer — 3 open to participants now, 6 under way, none of them phase 3. Hemophilia A · Bayer.

Enrollment
4th of 31
94 · median 27
Started
2011
with 3 others
Phase 3
7 of 57
none open now
Registered
18th of 57
by date

Among the 57 studies in Hemophilia A by Bayer, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2011, is one of 7 in phase 3, and was the 18th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

3 of the 57 studies in Hemophilia A by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 0 Years to 12 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hemophilia A by Bayer, or all of them as a file.
02

Study summary

The primary objective was to evaluate the safety and efficacy of the treatment with BAY81-8973 for prophylaxis and treatment of breakthrough bleeds in children with severe hemophilia A.

The secondary objectives were

  • To assess the safety and efficacy of BAY81-8973 during surgeries.
  • To assess incremental recovery of BAY81-8973.
  • To assess pharmacokinetic (PK) parameters in a subset of children (Previously treated patients [PTPs] and previously untreated patients [PUPs] / minimally treated patients [MTPs] - participation in PK sampling was voluntary and required consent).
03

Conditions studied

  • Haemophilia A

Browse trials for

Keywords

  • Recombinant factor VIII
  • Pediatric use
04

Who can participate

Ages eligible
0 Years to 12 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • PTPs (previously treated patients): aged \<= 12 years
  • PUPs (previously untreated patients) / MTPs (minimally treated patients): aged \< 6 years
  • Severe hemophilia A defined as \< 1% FVIII concentration (FVIII:C)
  • PTPs: >= 50 exposure days (EDs) with any FVIII concentrate, no current evidence of inhibitory antibody, and no history of FVIII inhibitor formation
  • PUPs: no prior exposure to any FVIII product
  • MTPs: having no more than 3 EDs with any FVIII product, no current evidence of inhibitory antibody and no history of FVIII inhibitor formation

Exclusion criteria

Exclusion Criteria:

  • With another bleeding disorder that is different from Hemophilia A
  • With thrombocytopenia ( count \< 100 000/mm\^3)
  • Creatinine > 2x or (AST)/Alanine aminotransferase (ALT) > 5x upper limit of normal
  • Without a negative inhibitor testing at screening (except for PUPs)
  • Receiving chemotherapy, immune modulatory drugs, has received another FVIII product within the last month, or received another experimental drug within the last 3 months
  • Requires any pre-medication to tolerate FVIII treatment
  • Known to active substance, mouse, or hamster protein
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    PTPs 0-12 years

    Previously treated patients (PTPs) aged below 12 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (EDs) in main study - Part A. Participants having reached at least 50 EDs in main study - Part A were offered participation in an open label extension study (optional). Participants who transitioned from main study - Part A to the extension study received BAY81-8973, 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study).

    Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)

  • Experimental
    PUPs/MTPs 0-<6 years

    Previously untreated patients (PUPs) or minimally treated patients (MTPs, patients who had no more than 3 exposure days (EDs) with any FVIII product) received BAY81-8973 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development in main study - Part B. Participants having reached at least 50 EDs in main study - Part B were offered participation in an open label extension study and received BAY81-8973 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study); participants who developed an inhibitor in main study - Part B were offered participation in open label extension study and received Immune Tolerance Induction (ITI) treatment with BAY81-8973 until successful eradication of the inhibitor, or until failure, for approximately 18 months.

    Biological: Recombinant Factor VIII (Kovaltry, BAY81-8973)

Interventions

  • BiologicalRecombinant Factor VIII (Kovaltry, BAY81-8973)

    Main study: 25-50 IU/kg at least 2x/week for 6 months and at least 50 EDs, IV infusion; Extension study: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study), IV infusion. Exposure day (ED): An ED is a unit of time (1 day) in which replacement treatment of Hemophilia is given to a patient.

  • BiologicalRecombinant Factor VIII (Kovaltry, BAY81-8973)

    Main study: 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development, IV infusion; Extension study: For participants having reached at least 50 EDs in main study - Part B: 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study), IV infusion. For participants who developed an inhibitor in main study - Part B: up to 200 IU/kg per day or 100 IU/kg twice a day at the discretion of the investigator and coordinating investigator until successful eradication of the inhibitor, or until failure, for up to18 months (treatment beyond 18 months required an agreement with the sponsor and coordinating investigator), IV infusion

06

What researchers measure

Primary outcomes

  1. Annualized Number of Total Bleeds Within 48 h

    Annualized number (mean +/- standard deviation) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \[EDs\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').

    Time frame: Within 48 hours post infusion

  2. Annualized Number of Total Bleeds Within 48 h

    Annualized number (median \[inter-quartile range (Q1-Q3)\]) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \[EDs\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').

    Time frame: Within 48 hours post infusion

Secondary outcomes

  1. Annualized Number of Total Bleeds During Prophylaxis Treatment

    Annualized number (mean +/- standard deviation) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  2. Annualized Number of Total Bleeds During Prophylaxis Treatment

    Annualized number (median \[inter-quartile range (Q1-Q3)\]) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  3. Hemostatic Control During Major and Minor Surgeries

    For participants who underwent major or minor surgeries during the study, hemostasis during the surgeries was assessed as excellent, good, moderate or poor. Number of surgeries per assessment was summarized and reported.

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  4. Number of Participants With Inhibitor Development in Main Study

    Number of participants with confirmed positive FVIII inhibitor titer (≥ 0.6 Bethesda unit \[BU/mL\]) during the main study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \> 5.0 BU/mL).

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  5. Number of Participants With New Inhibitor Development in Extension Study

    Number of participants who had not developed an inhibitor during the main study but developed an inhibitor (confirmed positive FVIII inhibitor titer \[≥ 0.6 BU/mL\]) during the extension study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \> 5.0 BU/mL).

    Time frame: From start of extension study to at least 100 cumulative exposure days (EDs) (median 421 EDs; median 3.8 years)

  6. Factor VIII Recovery Values

    Incremental recovery of Factor VIII (FVIII) at 20-30 min after end of infusions was determined and mean recovery values were reported.

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  7. Consumption of Factor VIII in All Infusions

    Factor VIII (FVIII) usage/consumption was summarized for all infusions. Consumption per participant's body weight per year was calculated and reported.

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  8. Consumption of FVIII in Infusions for Prophylaxis

    Factor VIII (FVIII) usage/consumption was summarized for prophylaxis infusions. Consumption per participant's body weight per year was calculated and reported.

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  9. Consumption of FVIII in Infusions for the Treatment of Bleeds

    Factor VIII (FVIII) usage/consumption was summarized for infusions used to treat breakthrough bleeds. Consumption per participant's body weight per year was calculated and reported.

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  10. Number of Infusions Per Bleed

    The number of infusions used to treat a bleed was defined as the first infusion to treat the bleed plus all follow-up infusions to treat the same bleed, if any. The mean value of number of infusions for each bleed was calculated and reported.

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  11. Response to Treatment of Bleeds

    Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Percentage of bleeds per assessment was summarized and reported.

    Time frame: Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)

  12. Half-life (t1/2) of BAY81-8973 in Plasma

    Half-life (t1/2) of BAY81-8973 in plasma was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.

    Time frame: Pre-infusion and until 24 hours post infusion

07

Results

Posted Nov 3, 2020
Limitations and caveats
Due to the small number of participants per reporting group, all presented summary measures (e.g. mean and proportion) have to be evaluated with caution. If displayed standard deviation should be taken into account. The participant who had a low titer inhibitor detected after 549 EDs during the extension study was considered to have a false positive result due to cross reactivity with IgG anticardiolipin antibodies.

Participant flow

The study was conducted at multiple centers in 18 countries and consisted of: Part A - between 09-JUN-2011 (FPFV) and 02-JAN-2013 (LPLV); Part B - between 19-SEP-2012 (FPFV) and 09-SEP-2019 (LPLV); Extension study - between 21-DEC-2011 (FPFV) and 27-OCT-2020 (LPLV).

Main Study
Participant flow — Main Study
MilestonePTPs 0-12 YearsPUPs/MTPs 0-<6 Years
Started5143
Started 0-<6 years2543
Started 6-12 years260
Completed5122
Not completed021
Withdrew: Protocol violation01
Withdrew: Adverse event01
Withdrew: Inhibitor management017
Withdrew: Withdrawal by subject02
Extension Study
Participant flow — Extension Study
MilestonePTPs 0-12 YearsPUPs/MTPs 0-<6 Years
Started4636
Completed4525
Not completed111
Withdrew: Physician decision01
Withdrew: Iti therapy with marketed product01
Withdrew: Incorrect visit planning01
Withdrew: Family's decision01
Withdrew: Failure of iti therapy03
Withdrew: Long travel01
Withdrew: Diagnosed with von willebrand disease10
Withdrew: Withdrawal by subject01
Withdrew: Inhibitor management02

Outcome measures

PrimaryAnnualized Number of Total Bleeds Within 48 h

Annualized number (mean +/- standard deviation) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \[EDs\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').

Time frame:
Within 48 hours post infusion
Reported as:
Mean · Bleeds
Annualized Number of Total Bleeds Within 48 h
BleedsMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Annualized Number of Total Bleeds Within 48 h2.23 ± 2.771.86 ± 3.081.9 ± 3.3
PrimaryAnnualized Number of Total Bleeds Within 48 h

Annualized number (median \[inter-quartile range (Q1-Q3)\]) of total bleeds that occurred within 48 hours after all prophylaxis infusions (Part A: 6 months and at least 50 exposure days \[EDs\]; Part B: at least 50 EDs or until inhibitor development) was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').

Time frame:
Within 48 hours post infusion
Reported as:
Median · Bleeds
Annualized Number of Total Bleeds Within 48 h
BleedsMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Annualized Number of Total Bleeds Within 48 h1.88 ± 0.000.00 ± 0.000.0 ± 0.0
SecondaryAnnualized Number of Total Bleeds During Prophylaxis Treatment

Annualized number (mean +/- standard deviation) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Mean · Bleeds
Annualized Number of Total Bleeds During Prophylaxis Treatment
BleedsMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Annualized Number of Total Bleeds During Prophylaxis Treatment4.16 ± 5.023.37 ± 5.017.1 ± 8.6
SecondaryAnnualized Number of Total Bleeds During Prophylaxis Treatment

Annualized number (median \[inter-quartile range (Q1-Q3)\]) of total bleeds that occurred during prophylaxis treatment was summarized and reported. Total bleeds: sum of spontaneous bleeds, trauma bleeds (only treated bleeds were classified as spontaneous or trauma), untreated bleeds and 'other' bleeds ('other' bleeds were infusions with reason given as 'other').

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Median · Bleeds
Annualized Number of Total Bleeds During Prophylaxis Treatment
BleedsMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Annualized Number of Total Bleeds During Prophylaxis Treatment2.03 ± 0.000.93 ± 0.004.7 ± 2.1
SecondaryHemostatic Control During Major and Minor Surgeries

For participants who underwent major or minor surgeries during the study, hemostasis during the surgeries was assessed as excellent, good, moderate or poor. Number of surgeries per assessment was summarized and reported.

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Count of units · Surgeries
Hemostatic Control During Major and Minor Surgeries
SurgeriesMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Minor surgery — Excellent003
Minor surgery — Good001
Minor surgery — Moderate000
Minor surgery — Poor000
Minor surgery — Not available001
Major surgery — Excellent000
Major surgery — Good011
Major surgery — Moderate000
Major surgery — Poor000
Major surgery — Not available000
SecondaryNumber of Participants With Inhibitor Development in Main Study

Number of participants with confirmed positive FVIII inhibitor titer (≥ 0.6 Bethesda unit \[BU/mL\]) during the main study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \> 5.0 BU/mL).

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Count of participants · Participants
Number of Participants With Inhibitor Development in Main Study
ParticipantsMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Low titer inhibitor006
High titer inhibitor0017
SecondaryNumber of Participants With New Inhibitor Development in Extension Study

Number of participants who had not developed an inhibitor during the main study but developed an inhibitor (confirmed positive FVIII inhibitor titer \[≥ 0.6 BU/mL\]) during the extension study was summarized and classified as participants developing low titer inhibitor (i.e. ≥ 0.6 to ≤ 5.0 BU/mL) and participants developing high titer inhibitor (i.e. \> 5.0 BU/mL).

Time frame:
From start of extension study to at least 100 cumulative exposure days (EDs) (median 421 EDs; median 3.8 years)
Reported as:
Count of participants · Participants
Number of Participants With New Inhibitor Development in Extension Study
ParticipantsExtension Study - Former Part A ParticipantsExtension Study - Former Part B Participants
Low titer inhibitor (incl. false-positive)10
High titer inhibitor00
SecondaryFactor VIII Recovery Values

Incremental recovery of Factor VIII (FVIII) at 20-30 min after end of infusions was determined and mean recovery values were reported.

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Mean · International unit (IU)/dL per IU/kg
Factor VIII Recovery Values
International unit (IU)/dL per IU/kgMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Participants without inhibitor1.63 ± 0.311.72 ± 0.461.76 ± 0.55
Participants with low titer inhibitor——0.86 ± 0.56
Participants with high titer inhibitor——0.38 ± 0.42
SecondaryConsumption of Factor VIII in All Infusions

Factor VIII (FVIII) usage/consumption was summarized for all infusions. Consumption per participant's body weight per year was calculated and reported.

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Mean · international units/kilogram/year
Consumption of Factor VIII in All Infusions
international units/kilogram/yearMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Consumption of Factor VIII in All Infusions5499.1 ± 1996.24679.1 ± 1688.72195.8 ± 1903.6
SecondaryConsumption of FVIII in Infusions for Prophylaxis

Factor VIII (FVIII) usage/consumption was summarized for prophylaxis infusions. Consumption per participant's body weight per year was calculated and reported.

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Mean · international units/kilogram/year
Consumption of FVIII in Infusions for Prophylaxis
international units/kilogram/yearMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Consumption of FVIII in Infusions for Prophylaxis5224.8 ± 1760.24492.7 ± 1667.61486.6 ± 963.3
SecondaryConsumption of FVIII in Infusions for the Treatment of Bleeds

Factor VIII (FVIII) usage/consumption was summarized for infusions used to treat breakthrough bleeds. Consumption per participant's body weight per year was calculated and reported.

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Mean · international units/kilogram/year
Consumption of FVIII in Infusions for the Treatment of Bleeds
international units/kilogram/yearMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Consumption of FVIII in Infusions for the Treatment of Bleeds457.07 ± 526.87391.64 ± 219.61835.4 ± 1926.4
SecondaryNumber of Infusions Per Bleed

The number of infusions used to treat a bleed was defined as the first infusion to treat the bleed plus all follow-up infusions to treat the same bleed, if any. The mean value of number of infusions for each bleed was calculated and reported.

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Mean · Infusions
Number of Infusions Per Bleed
InfusionsMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Number of Infusions Per Bleed1.3 ± 1.81.4 ± 1.71.7 ± 8.7
SecondaryResponse to Treatment of Bleeds

Participants or caregivers were asked to assess the response to treatment of bleeds as excellent, good, moderate or poor. Percentage of bleeds per assessment was summarized and reported.

Time frame:
Part A: 6 months and at least 50 exposure days (EDs) (median 73 EDs; median 6 months); Part B: at least 50 EDs or until inhibitor development (median 46 EDs; median 8 months)
Reported as:
Count of units · Bleeds assessed for the response
Response to Treatment of Bleeds
Bleeds assessed for the responseMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 Years
Excellent201227
Good231856
Moderate0716
Poor106
SecondaryHalf-life (t1/2) of BAY81-8973 in Plasma

Half-life (t1/2) of BAY81-8973 in plasma was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.

Time frame:
Pre-infusion and until 24 hours post infusion
Reported as:
Geometric mean · Hours
Half-life (t1/2) of BAY81-8973 in Plasma
HoursMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 Years
Half-life (t1/2) of BAY81-8973 in Plasma13.2 ± 39.712.1 ± 16.3

Adverse events

Collected over Main study - Part A: from the first BAY81-8973 infusion until 3 days after the last infusion (median 6 months); Main study - Part B: from the first BAY81-8973 infusion until 7 days after the last infusion (median 8 months); Extension: from start of extension study until 3 days after the last infusion in extension study (median 3.1 years). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Study - Part A: PTPs 0-<6 Years0/25 (0%)0/25 (0%)16/25 (64%)
Main Study - Part A: PTPs 6-12 Years0/26 (0%)5/26 (19.2%)19/26 (73.1%)
Main Study - Part B: PUPs/MTPs 0-<6 Years0/43 (0%)26/43 (60.5%)28/43 (65.1%)
Extension Study - Former Part A Participants0/46 (0%)23/46 (50%)41/46 (89.1%)
Extension Study - Former Part B Participants0/36 (0%)14/36 (38.9%)24/36 (66.7%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 YearsExtension Study - Former Part A ParticipantsExtension Study - Former Part B Participants
Anti factor VIII antibody positiveInvestigations0/250/2622/431/460/36
Central venous catheterisationSurgical and medical procedures0/250/261/432/464/36
Vascular device infectionInfections and infestations0/250/260/432/463/36
HaemarthrosisMusculoskeletal and connective tissue disorders0/250/263/431/463/36
Blood loss anaemiaBlood and lymphatic system disorders0/251/260/430/462/36
Catheter site haemorrhageGeneral disorders0/250/260/430/462/36
Gastroenteritis rotavirusInfections and infestations0/250/260/430/462/36
Central venous catheter removalSurgical and medical procedures0/250/260/431/462/36
Immune tolerance inductionSurgical and medical procedures0/250/260/430/462/36
Soft tissue haemorrhageMusculoskeletal and connective tissue disorders0/250/262/430/460/36
Most frequent other events
Showing 10 of 111
Most frequent other events
EventMain Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 YearsExtension Study - Former Part A ParticipantsExtension Study - Former Part B Participants
PyrexiaGeneral disorders5/252/2612/438/4611/36
NasopharyngitisInfections and infestations2/252/266/4313/469/36
TonsillitisInfections and infestations1/251/261/4310/460/36
Limb injuryInjury, poisoning and procedural complications0/251/260/439/461/36
CoughRespiratory, thoracic and mediastinal disorders2/254/261/439/463/36
HeadacheNervous system disorders2/254/260/438/460/36
VomitingGastrointestinal disorders1/251/264/434/466/36
DiarrhoeaGastrointestinal disorders2/251/266/435/461/36
RhinitisInfections and infestations1/251/263/436/461/36
Upper respiratory tract infectionInfections and infestations1/251/263/436/462/36

Baseline characteristics

Safety analysis set (SAF): all participants who entered Study Part A or Part B and received at least one infusion of study medication.

Age, Continuous
Age, Continuous(Years)Main Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 YearsTotal
Mean3.8 ± 1.38.8 ± 1.81.1 ± 0.83.9 ± 3.4
Sex: Female, Male
Sex: Female, Male(Participants)Main Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 YearsTotal
Female0000
Male25264394
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 YearsTotal
Hispanic or Latino10910
Not Hispanic or Latino23253482
Unknown or Not Reported1102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Main Study - Part A: PTPs 0-<6 YearsMain Study - Part A: PTPs 6-12 YearsMain Study - Part B: PUPs/MTPs 0-<6 YearsTotal
White24243785
Black1214
American Indian or Alaska native0011
White, American Indian or Alaska native0011
Not reported0033
08

Study locations

43 sites
  • New Orleans, Louisiana 70112, United States
  • Cincinnati, Ohio 45229, United States
  • Cleveland, Ohio 44106, United States
  • Columbus, Ohio 43205-2696, United States
  • Bahía Blanca, Buenos Aires B8001HXM, Argentina
  • Plovdiv, 4002, Bulgaria
  • Varna, 9010, Bulgaria
  • Edmonton, Alberta T6G 2C8, Canada
  • Hamilton, Ontario L8N 3Z5, Canada
  • Toronto, Ontario M5G 1X8, Canada
  • Århus N, 8200, Denmark
  • Budapest, 1089, Hungary
  • Debrecen, 4032, Hungary
  • Mohacs, 7700, Hungary
  • Crumlin, Dublin 12, Ireland
  • Ramat Gan, 5262000, Israel
  • Roma, Lazio 00165, Italy
  • Milano, Lombardia 20122, Italy
  • Bari, Puglia 70126, Italy
  • Catania, Sicilia 95123, Italy
  • Padova, Veneto 35128, Italy
  • Riga, LV-1004, Latvia
  • Vilnius, 08406, Lithuania
  • Guadalajara, Jalisco 44280, Mexico
  • San Juan del Río, Querétaro 76800, Mexico
  • Oaxaca, 68000, Mexico
  • Oslo, Norway
  • Lodz, 91-738, Poland
  • Warszawa, 00-576, Poland
  • Wroclaw, 50-368, Poland
  • Bucharest, 011026, Romania
  • Bucharest, 022328, Romania
  • Cluj-Napoca, 400177, Romania
  • Timisoara, 300011, Romania
  • Kazan, 139445, Russian Federation
  • Kirov, 610027, Russian Federation
  • Volgograd, 400138, Russian Federation
  • Esplugues de LLobregat, Barcelona 8950, Spain
  • A Coruña, 15006, Spain
  • Alicante, 03010, Spain
  • Cáceres, 10003, Spain
  • Madrid, 28046, Spain
  • Valencia, 46026, Spain
09

References and documents

Publications

  • Oldenburg J, Windyga J, Hampton K, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Maas Enriquez M. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. Haemophilia. 2016 May;22(3):349-53. doi: 10.1111/hae.12839. Epub 2016 Mar 1. PubMed 26931631 ↗
  • Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, Michaels LA, Shah A, Hong W, Maas Enriquez M; investigators of the LEOPOLD Kids Trial. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia. 2016 May;22(3):354-60. doi: 10.1111/hae.12866. Epub 2015 Dec 9. PubMed 26663410 ↗
  • Keating GM. BAY 81-8973 (Octocog Alfa; Kovaltry(R)): A Review in Haemophilia A. BioDrugs. 2016 Oct;30(5):453-459. doi: 10.1007/s40259-016-0191-4. PubMed 27577234 ↗
  • Shah A, Delesen H, Garger S, Lalezari S. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII. Haemophilia. 2015 Nov;21(6):766-71. doi: 10.1111/hae.12691. Epub 2015 May 8. PubMed 25952661 ↗
  • Maas Enriquez M, Thrift J, Garger S, Katterle Y. BAY 81-8973, a full-length recombinant factor VIII: Human heat shock protein 70 improves the manufacturing process without affecting clinical safety. Protein Expr Purif. 2016 Nov;127:111-115. doi: 10.1016/j.pep.2016.07.009. Epub 2016 Jul 18. PubMed 27436242 ↗
  • Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia. 2017 Jul;23(4):528-537. doi: 10.1111/hae.13192. Epub 2017 Feb 20. PubMed 28220555 ↗
  • Mahlangu JN, Ahuja SP, Windyga J, Church N, Shah A, Schwartz L. BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review. Ther Adv Hematol. 2018 Jul;9(7):191-205. doi: 10.1177/2040620718777903. Epub 2018 Jun 12. PubMed 30013766 ↗
  • Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 May;189:96-101. doi: 10.1016/j.thromres.2020.03.005. Epub 2020 Mar 9. PubMed 32197139 ↗
  • Kenet G, Moulton T, Wicklund BM, Ahuja SP, Escobar M, Mahlangu J. Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials. J Blood Med. 2023 Jun 7;14:379-388. doi: 10.2147/JBM.S405624. eCollection 2023. PubMed 37309365 ↗
  • Ljung R, Chan AKC, Glosli H, Afonja O, Becker B, Tseneklidou-Stoeter D, Mancuso ME, Saulyte-Trakymiene S, Kenet G. BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial. Thromb Haemost. 2023 Jan;123(1):27-39. doi: 10.1055/s-0042-1757876. Epub 2023 Jan 10. PubMed 36626898 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Sep 2019, 99 months.

Results were first posted in Nov 2020, 1 year 1 month after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 99 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2011
First posted
Mar 9, 2011
StartActual
Jun 9, 2011
Primary completionActual
Sep 9, 2019
CompletionActual
Oct 27, 2020
Results first posted
Nov 3, 2020
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01311648
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 9, 2011
Start date
Jun 9, 2011
Primary completion
Sep 9, 2019
Completion
Oct 27, 2020
Results posted
Nov 3, 2020
Last update
Dec 5, 2023

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion